Every 8-K that Aardvark Therapeutics, Inc. (AARD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AARD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AARD filings page.
Aardvark Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders held on August 14, 2026. Of 21,884,158 common shares outstanding as of the June 18, 2026 record date, 11,992,479 shares were represented, forming a 54.79% quorum. Stockholders elected Class I directors Victor Tong, Jr. and Jeffrey Chi, Ph.D. to serve until the 2029 annual meeting or until successors are elected and qualified. Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026. In addition, stockholders approved the repricing of certain outstanding stock options under the 2017 Plan, the 2025 Plan and the 2025 Inducement Plan held by eligible participants, based on the stated voting results.
Aardvark Therapeutics reported second quarter 2026 results and major pipeline developments for ARD-101 in Prader-Willi Syndrome. The company is assessing unblinded Phase 3 HERO and Open Label Extension data in the third quarter of 2026 to determine next steps after terminating both trials in June 2026. In May 2026, the FDA placed a full clinical hold on the ARD-101 investigational new drug application, covering all ongoing studies.
Aardvark held $73.9 million in cash, cash equivalents and short-term investments as of June 30, 2026, which it believes will fund operations into late 2027. Second quarter 2026 research and development expenses were $10.5 million, down from $13.1 million a year earlier, while general and administrative expenses increased to $4.6 million from $2.7 million. Net loss was $14.4 million, consistent with the prior-year quarter, and total assets declined to $81.5 million from $117.2 million at December 31, 2025.
Aardvark Therapeutics, Inc. approved cash retention arrangements for two senior executives. On June 10, 2026, the company entered into a retention bonus agreement with Chief Financial Officer and Chief Operating Officer Nelson Sun, providing a total potential cash retention bonus of $346,500 for 2026. This consists of a $198,000 guaranteed annual bonus and a $148,500 retention portion, payable on January 1, 2027 if he remains employed through that date or if he experiences certain qualifying terminations.
The company also entered into a similar agreement with Chief Medical Officer Manasi Jaiman, M.D., M.P.H., granting a total retention bonus opportunity of $357,000 for 2026, made up of a $204,000 guaranteed bonus and a $153,000 retention bonus. This amount is also payable on January 1, 2027, subject to continued employment or specified termination conditions, and in each case conditioned on an irrevocable release of claims in a company-prescribed form.
Aardvark Therapeutics disclosed that the U.S. Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101. The hold covers all ongoing studies, including the Phase 3 HERO trial in Prader-Willi Syndrome and its open-label extension.
The company is in active discussions with the FDA and plans to unblind accumulated data from both HERO and the OLE trial to evaluate overall safety and efficacy and guide next steps for the ARD-101 program. As of February 27, 2026, 68 patients had been dosed in HERO and 19 in the OLE trial.
As of March 31, 2026, Aardvark reported $91.2 million in cash, cash equivalents and short-term investments, which it believes will fund projected operations into mid-2027 while it assesses ARD-101 and continues its broader hunger- and metabolic-disease pipeline.
Aardvark Therapeutics reported first quarter 2026 results and detailed a voluntary pause of its lead clinical programs. The Phase 3 HERO and open-label extension trials of ARD-101 in Prader-Willi Syndrome, and development of ARD-201 for obesity, are on hold after reversible cardiac observations in a separate healthy volunteer study.
The company is working with the FDA and expects further guidance on both programs in the second quarter of 2026. Aardvark ended March 31, 2026 with $91.2 million in cash, cash equivalents and short-term investments, which it believes will fund operations into mid-2027.
First quarter 2026 research and development expenses rose to $16.6 million from $7.8 million a year earlier, while general and administrative costs increased to $5.9 million from $2.7 million, reflecting higher ARD-101 development and public company costs. Net loss widened to $21.6 million, or $0.99 per share, compared with a $9.3 million loss, or $0.71 per share, in the prior-year period.
Aardvark Therapeutics, Inc. entered into an Equity Distribution Agreement with Piper Sandler & Co. allowing it to sell, from time to time, shares of its common stock through or to Piper Sandler as sales agent. These shares will be issued under an existing shelf registration statement on Form S-3.
Under the related prospectus, the company may offer and sell shares with an aggregate offering price of up to $150,000,000. Piper Sandler will receive a commission of 3.0% of the gross sales price per share sold. Aardvark has no obligation to sell any shares under this arrangement.
Aardvark Therapeutics reported fourth quarter and full-year 2025 results and announced significant pipeline changes. The company has voluntarily paused enrollment and dosing in its Phase 3 HERO and OLE trials of ARD-101 for Prader-Willi Syndrome, and also paused its ARD-201 obesity trials, after reversible cardiac QRS prolongation was seen in high-dose healthy volunteer studies. Aardvark is working with the FDA and expects further guidance on both programs in the second quarter of 2026. As of December 31, 2025, it held $110.0 million in cash, cash equivalents and short-term investments, which it believes will fund operations into the second quarter of 2027. Full-year 2025 R&D expenses rose to $48.9 million and G&A expenses to $13.8 million, driving a net loss of $57.6 million, compared with a net loss of $20.6 million in 2024. The company also highlighted published clinical and preclinical ARD-101 data showing reduced hunger scores and favorable gut hormone changes in prior studies.
Aardvark Therapeutics has voluntarily paused its Phase 3 HERO trial of ARD-101 in Prader-Willi syndrome, along with the related open-label extension. The pause follows reversible cardiac observations at above target therapeutic doses seen during routine safety monitoring in a healthy volunteer study.
The company is conducting a comprehensive data review and has temporarily halted enrollment and dosing in HERO out of caution. As a result, Aardvark no longer expects to report topline HERO data in the third quarter of 2026 and plans to give updated timing guidance in the second quarter of this year.
Aardvark Therapeutics filed a current report describing leadership changes and the creation of a new dermatology-focused subsidiary. The company formed Ardia Therapeutics, a wholly owned U.S. unit that will develop DIA-615, a clinic-ready topical candidate for inflammatory skin diseases such as psoriasis.
Former Chief Operating Officer Bryan Jones, Ph.D., became Ardia’s Chief Executive Officer and entered a letter agreement covering salary through up to nine months after his transition, continued option exercisability while employed at Ardia, and accelerated vesting of 17,797 stock options plus monthly vesting of 2,542 additional options for three months. Nelson Sun, already Chief Financial Officer, was appointed Chief Operating Officer as well, with no material compensation change, and Derrick C. Li was named Chief Business Officer. The filing reiterates Aardvark’s core pipeline, including Phase 3 oral ARD-101 for Prader-Willi syndrome and Phase 2 combination candidate ARD-201 for obesity-related conditions.
Aardvark Therapeutics, Inc. announced U.S. Institutional Review Board approval of an amended protocol for its Phase 3 HERO trial of lead candidate ARD-101 in Prader-Willi Syndrome. The change lowers the minimum enrollment age from 10 to 7 years for U.S. participants.
The randomized, double-blind, placebo-controlled HERO study plans to enroll 90 patients across the U.S., Australia, Canada, the U.K. and South Korea, measuring change in Hyperphagia Questionnaire for Clinical Trials scores at Week 12 as the primary endpoint. Enrollment is described as progressing steadily, with topline data targeted for the third quarter of 2026.
Aardvark Therapeutics, Inc. filed a current report to note that on January 12, 2026 it updated its corporate presentation. The presentation, dated January 2026, is intended for meetings with investors, analysts and other stakeholders and will also be posted on the company’s website.
The updated corporate presentation is furnished as Exhibit 99.1 and is incorporated by reference into the Other Events section. The company states the presentation is current as of January 12, 2026 and disclaims any obligation to update this material in the future.
Aardvark Therapeutics, Inc. furnished a Form 8-K to announce a press release with financial results for the third quarter ended September 30, 2025, along with pipeline and business updates. The press release is provided as Exhibit 99.1, dated November 13, 2025.
The company states the information in Item 2.02 (including Exhibit 99.1) is furnished, not filed, and is not subject to Section 18 liabilities or incorporated by reference except as specifically noted. The filing also includes the Cover Page Interactive Data File as Exhibit 104. Aardvark’s common stock (AARD) is listed on The Nasdaq Stock Market LLC.
Aardvark Therapeutics filed an 8-K announcing it hosted an investor webinar on November 5, 2025 to review its ARD-101 and ARD-201 programs and its ObesityWeek 2025 presentations. The slide deck used is posted on the company’s website and is filed as Exhibit 99.1. The presentation is current as of November 5, 2025, and the company disclaims any obligation to update the material.
Aardvark Therapeutics (AARD) furnished an update under Regulation FD about new scientific disclosures at ObesityWeek 2025. The company presented two posters: “TAS2R Agonist ARD-101 Attenuates Weight Gain in Mice and Reduces Hunger in Adults with Obesity” and “An Isoflavonoid Modulator of Oxidative Metabolism with Therapeutic Potential in Obesity and Diabetes.” It also announced an investor webinar on November 5, 2025 covering ARD-101, ARD-201, and the conference data.
The materials are provided as Exhibits 99.1, 99.2, and 99.3 and are furnished, not filed, under the Exchange Act.
Aardvark Therapeutics, Inc. reported that it has reached alignment with the U.S. Food and Drug Administration on a protocol amendment to its Phase 3 HERO trial of ARD-101 for treating hyperphagia associated with Prader-Willi Syndrome.
The amendment lowers the minimum age for trial eligibility from 13 to 10 years old, allowing younger patients with this condition to participate in the Phase 3 study. The company announced this change in a press release dated October 8, 2025, which is included as an exhibit to the report.
Aardvark Therapeutics, Inc. reported that it issued a press release on August 13, 2025 detailing its financial results for the second quarter ended June 30, 2025, along with updates on its drug development pipeline and overall business. The press release is provided as Exhibit 99.1 and gives the full results and operational commentary.
The company specifies that this press release and related information are being furnished rather than filed, meaning they are not subject to certain legal liabilities under the Securities Exchange Act and are not automatically incorporated into other securities law documents unless specifically referenced.
Aardvark Therapeutics disclosed via this Current Report that it issued a press release announcing new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. The company states the full text of the press release is filed as Exhibit 99.1 to the report and is incorporated by reference.
The filing does not include clinical data, quantitative results, financial statements, or a timetable for next steps; the report also identifies the registrant as an emerging growth company. Consult Exhibit 99.1 for the full press release text and any data not contained in the 8-K.